DENTSPLY SIRONA Inc. (XRAY) Cash Flow Statement

The persistent gap between net income and operating cash flow, particularly in quarters like 2025Q3 where OCF was positive despite a -$427M net loss, suggests that reported losses are heavily influenced by non-cash charges such as impairments and depreciation. However, the 2026Q2 OCF/NI of 3.76, while superficially strong, is inflated by a modest net income of $37M against $139M OCF, indicating that cash generation is not translating into sustainable profitability. Investors should monitor whether this divergence narrows as non-recurring charges fade.

The erratic FCF trajectory, with 2024Q2's $156M FCF contrasting sharply with 2026Q1's -$12M, suggests that working capital swings and capex timing are driving volatility rather than stable underlying operations. The 2026Q2 FCF margin of 4.8% is well below the 15.9% seen in 2024Q2, implying a deterioration in cash conversion efficiency. This inconsistency aligns with the prior income statement analysis showing revenue contraction and suggests that FCF growth is not yet on a reliable upward path.

The rising CapEx/Rev ratio, from 3.6% to 10.7% over the period, suggests that XRAY is investing in capital assets at a pace that outpaces its revenue growth, potentially signaling a bet on future expansion or necessary maintenance. However, with revenue declining 4.1% year-over-year in 2026Q2, this increased capital outlay may strain free cash flow if returns do not materialize. The absolute CapEx of $96M in 2026Q2 is the highest in the series, warranting scrutiny into whether this represents growth initiatives or catch-up maintenance.

The large swings in working capital, such as the -$113M in 2025Q2 and +$97M in 2024Q2, suggest that XRAY's cash flow is heavily influenced by timing of receivables, inventory, and payables, rather than stable operational efficiency. The 2026Q2 working capital drag of -$92M, which offset much of the operating cash flow, may indicate inventory build-up or slower collections, though the data does not specify the components. This volatility complicates forecasting and suggests that management may be using working capital levers to manage cash flow, which warrants close monitoring.

XRAY has consistently paid dividends of around $32M quarterly, even during periods of negative net income, which may indicate a commitment to shareholder returns but also raises questions about sustainability given strained profitability. Buybacks were only executed in 2024Q2 and Q3, totaling $250M, but have been zero since, suggesting a shift away from repurchases to preserve cash. The lack of acquisition activity in the data implies that capital deployment is focused on dividends and internal investment, though the modest FCF may limit future flexibility.

The cumulative divergence between net income and operating cash flow is stark, with net losses of $1.46B against positive OCF of $875M, indicating that reported losses are largely non-cash in nature, such as impairments and depreciation. This suggests that the company's cash-generating ability is stronger than its earnings suggest, but it also highlights the risk that future cash flows may be needed to cover restructuring or legal costs. Investors should recognize that the gap may narrow as non-recurring charges subside, but the underlying operational profitability remains weak.